Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
The Lancet. Neurology
|
May 17, 2024
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease - Author's reply
Andrew McGarry
Neurology
|
April 8, 2020
Author response: Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial
Andrew McGarry
Parkinsonism & Related Disorders
|
April 9, 2013
Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and Parkinsonism
Andrew McGarry, Kevin Biglan
Handbook of Clinical Neurology
|
February 21, 2023
Adaptive clinical trials and master protocols
Andrew McGarry, Karl Kieburtz
Brain Sciences
|
January 24, 2025
A Pilot Proteomic Analysis of Huntington's Disease by Functional Capacity
Andrew McGarry, Ruin Moaddel
Handbook of Clinical Neurology
|
September 27, 2017
Preclinical motor manifestations of Huntington disease
Andrew McGarry, Kevin M Biglan
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 7, 2020
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic
Karl Kieburtz, Russell Katz, Andrew McGarry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 15, 2011
Pharmacologic approaches to the treatment of Huntington's disease
Charles S Venuto, Andrew McGarry, Qing Ma, et al.
Journal of Huntington'S Disease
|
January 28, 2020
Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington's Disease
Andrew McGarry, Michael P McDermott, Karl Kieburtz, et al.
Clinical Parkinsonism & Related Disorders
|
January 23, 2026
Explore thyself: is it time for metacognition screening in clinical trials?
Andrew McGarry, Scott Y H Kim, Peggy Auinger, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
The Lancet. Neurology
|
May 17, 2024
Negative findings from trials with NLY01 or deferiprone for Parkinson's disease - Author's reply
Andrew McGarry
Neurology
|
April 8, 2020
Author response: Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial
Andrew McGarry
Parkinsonism & Related Disorders
|
April 9, 2013
Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and Parkinsonism
Andrew McGarry, Kevin Biglan
Handbook of Clinical Neurology
|
February 21, 2023
Adaptive clinical trials and master protocols
Andrew McGarry, Karl Kieburtz
Brain Sciences
|
January 24, 2025
A Pilot Proteomic Analysis of Huntington's Disease by Functional Capacity
Andrew McGarry, Ruin Moaddel
Handbook of Clinical Neurology
|
September 27, 2017
Preclinical motor manifestations of Huntington disease
Andrew McGarry, Kevin M Biglan
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 7, 2020
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic
Karl Kieburtz, Russell Katz, Andrew McGarry, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 15, 2011
Pharmacologic approaches to the treatment of Huntington's disease
Charles S Venuto, Andrew McGarry, Qing Ma, et al.
Journal of Huntington'S Disease
|
January 28, 2020
Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington's Disease
Andrew McGarry, Michael P McDermott, Karl Kieburtz, et al.
Clinical Parkinsonism & Related Disorders
|
January 23, 2026
Explore thyself: is it time for metacognition screening in clinical trials?
Andrew McGarry, Scott Y H Kim, Peggy Auinger, et al.
Page
of 4